A newly published review paper highlights the emerging importance of the immunoproteasome in the onset and progression of diabetes and its wide range of complications, providing new perspectives for future therapeutic strategies. This discovery positions this specialized protein complex as an important regulator of inflammation, metabolism, and cellular health.
Immunoproteasomes, a modified form of proteasomes responsible for protein degradation, play a central role in maintaining cellular balance and immune responses. Increasing evidence indicates that it directly affects pancreatic β-cell function, glucose metabolism, and lipid regulation, all important processes that are disrupted in diabetes.
In type 1 diabetes, immunoproteasomes contribute to immune-induced damage to insulin-producing cells by forming antigen presentation and activating immune pathways. In type 2 diabetes, it plays a more complex role, promoting chronic inflammation while protecting cells from stress-induced damage. This dual function highlights its importance as both a cause of disease and a potential defense mechanism.
This review also highlights the involvement of immunoproteasomes in major diabetes-related complications such as cardiovascular disease, renal damage, and retinopathy. Increased activity of specific subunits is associated with increased fibrosis, oxidative stress, and inflammatory signaling, all of which contribute to organ dysfunction. At the same time, targeted modulation of these pathways shows the potential to improve outcomes by restoring metabolic balance and reducing tissue damage.
Particular attention has been focused on the influence of the immunoproteasome on glycolipid metabolism, which influences energy regulation and insulin sensitivity. Modulating its activity is associated with improved metabolic efficiency, reduced fat accumulation, and improved glucose disposal, pointing to new avenues for intervention.
The paper further identifies several promising treatments, including selective inhibitors that target key immunoproteasome subunits. These compounds have demonstrated the ability to reduce inflammation, limit fibrosis, and improve metabolic health, suggesting new types of treatments for managing both diabetes and its complications.
Overall, this review highlights that the immunoproteasome is a pleiotropic regulator in diabetes, bridging immune responses and metabolic processes. This study opens the door to innovative strategies aimed at improving understanding of the mechanisms, improving patient outcomes, and addressing the growing global burden of diabetes.
sauce:
Reference magazines:
Wang, M. others. (2026) Role of immunoproteasomes in diabetes and diabetes-related complications. genes and diseases. DOI: 10.1016/j.gendis.2025.101861. https://www.sciencedirect.com/science/article/pii/S2352304225003502?via%3Dihub
